{"id":9343,"date":"2018-08-17T00:00:00","date_gmt":"2018-08-17T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/index.php\/2018\/08\/17\/fda-permits-marketing-of-brain-stimulation-device-for-ocd\/"},"modified":"2018-08-20T16:05:42","modified_gmt":"2018-08-20T16:05:42","slug":"fda-permits-marketing-of-brain-stimulation-device-for-ocd","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2018\/08\/17\/fda-permits-marketing-of-brain-stimulation-device-for-ocd\/","title":{"rendered":"FDA Permits Marketing of Brain Stimulation Device for OCD"},"content":{"rendered":"<h3>FDA previously approved transcranial magnetic stimulation for major depression, certain migraines<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>FRIDAY, Aug. 17, 2018 (HealthDay News) &#8212; A brain stimulation device to treat obsessive-compulsive disorder (OCD) has received approval for marketing by the U.S. Food and Drug Administration.<\/p>\n<p>Transcranial magnetic stimulation uses magnetic fields to stimulate nerve cells in the brain. The FDA approved it as a treatment for major depression in 2008 and for treating pain associated with certain migraines in 2013.<\/p>\n<p>The approval of the Brainsway Deep Transcranial Magnetic Stimulation System was based on a study of 100 OCD patients. Thirty-eight percent of those treated with the device had a more than 30 percent reduction in the severity of their symptoms, compared with 11 percent of those treated with a sham device. No serious reactions to treatment with the device were reported, according to the FDA.<\/p>\n<p>&#8220;Transcranial magnetic stimulation has shown its potential to help patients suffering from depression and headaches,&#8221; Carlos Pena, Ph.D., director of the division of neurological and physical medicine devices at the FDA&#8217;s Center for Devices and Radiological Health, said in a statement. &#8220;With today&#8217;s marketing authorization, patients with OCD who have not responded to traditional treatments now have another option.&#8221;<\/p>\n<p><a href=\"https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm617244.htm\" target=\"_new\">More Information<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2018 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\">HealthDay<\/a>. All rights reserved.<\/i>   <\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA previously approved transcranial magnetic stimulation for major depression, certain migraines<\/p>\n","protected":false},"author":6,"featured_media":9359,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-9343","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/9343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=9343"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/9343\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/9359"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=9343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=9343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=9343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}